Zimmer Biomet Holdings, Inc.
Financials
Valuation Metrics
Zimmer Biomet Holdings, Inc.'s Market Cap is $18.76B. At end of 2025 it was $17.73B. Ranked #628 of 3,112 in US market (top 20%), #436 of 1,667 on NYSE (top 26%), #43 of 206 in Health Care Equipment & Services (top 21%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $18.76B | US#628/3,112 Sec#43/206 |
| Revenue | $8.41B | US#655/3,112 Sec#36/206 |
| Net Income | $761M | US#636/3,112 Sec#40/206 |
| Total Assets | $22.72B | US#566/3,112 Sec#27/206 |
| Net Assets | $12.67B | US#342/3,112 Sec#20/206 |
| Employees | 17,000 | US#416/3,112 Sec#39/206 |
| Value | ||
| P/E | 24.65x | US#1,270/3,112 Sec#38/206 |
| P/B | 1.48x | US#803/3,112 Sec#45/206 |
| PEG | 0.80x | US#746/3,112 Sec#28/206 |
| P/S | 2.23x | US#1,382/3,112 Sec#99/206 |
| EV/EBITDA | 11.70x | US#1,017/3,112 Sec#32/206 |
| FCF Yield | 9.78% | US#525/3,112 Sec#21/206 |
| Profitability | ||
| ROE | 6.01% | US#1,760/3,112 Sec#83/206 |
| ROA | 3.35% | US#1,314/3,112 Sec#83/206 |
| Op. Margin | 15.61% | US#1,192/3,112 Sec#44/206 |
| Revenue Growth | 9.30% | US#1,355/3,112 Sec#96/206 |
| Earnings Growth | 30.82% | US#758/3,112 Sec#33/206 |
| Financial Health | ||
| Debt Ratio | 79.22% | US#871/3,112 Sec#91/206 |
| Total Debt | $7.47B | US#494/3,112 Sec#27/206 |
| FCF | $1.84B | US#370/3,112 Sec#22/206 |
| Cash | $424M | US#1,185/3,112 Sec#71/206 |
| Current Ratio | 1.73x | US#1,453/3,112 Sec#130/206 |
| Net Debt/EBITDA | 3.19x | US#1,711/3,112 Sec#102/206 |
| Dividend | ||
| Div. Yield | 1.01% | US#1,297/3,112 Sec#27/206 |
| Div. Growth | -0.40% | US—/3,112 Sec—/206 |
| Performance | ||
| 1Y Return | 7.58% | US#1,899/3,112 Sec#128/206 |
| 1M Return | 10.89% | US#482/3,112 Sec#45/206 |
| From 52W High | -9.97% | US#1,041/3,112 Sec#75/206 |
| 1Y MDD | -25.74% | US#1,084/3,112 Sec#30/206 |
| Trading | ||
| Volume | 1,672,094 shares | US#1,033/3,112 Sec#62/206 |
| Trading Value | $161M | US#620/3,112 Sec#47/206 |
| Per Share | ||
| EPS | $3.58 | US#864/3,112 Sec#52/206 |
| BPS | $64.43 | US#268/3,112 Sec#20/206 |
Company Info
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.